Pulmonary Embolism Prophylaxis in Patients With COVID-19: An Emerging Issue - 02/09/21
, Charalampos Grassos, MD, PhD b, Dimitrios Papadopoulos, MD, PhD a, Maria Velliou, MD a, John Barbetseas, MD, PhD a
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Severe acute respiratory syndrome (SARS)-CoV-2 virus disease (coronavirus disease 2019; COVID-19) is associated with increased coagulation activity, resulting in an excessive risk of venous thromboembolism (VTE) and poor prognosis. The most common manifestation of VTE is pulmonary embolism (PE), with approximately one in five hospitalised patients being at risk. These reports led to the empirical use of prophylactic anticoagulation, even in the absence of established or clinically suspected disease. This review summarises current aspects and recommendations regarding the use of thromboprophylaxis for PE in patients with COVID-19.
Le texte complet de cet article est disponible en PDF.Keywords : COVID-19, Pulmonary embolism, Coagulopathy, Thromboprophylaxis
Plan
Vol 30 - N° 10
P. 1435-1441 - octobre 2021 Retour au numéro
Article précédent
- Extracorporeal Membrane Oxygenation (ECMO) – Time is of the Essence!
- Jaishankar Raman, Steven C. Musca, Yvette L. O’Brien
- Translation and Impact of Funded Australian Cardiovascular Research: A Review With Perspective
- Alexis J. Hure, Shanthi Ramanathan, Simon Deeming, Gemma A. Figtree, Garry Jennings, Jacqui Webster, Rachael L. Morton, Julie Redfern, Kerry Doyle, Stephen J. Nicholls, Stephanie Blows, Catherine Kellick, Martin McNamara, Andrew Searles
Bienvenue sur EM-consulte, la référence des professionnels de santé.